Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone
Status:
Unknown status
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of Ramosetron, Aprepitant and
Dexamethasone therapy versus Ondansetron, Aprepitant and Dexamethasone therapy for preventing
of nausea and vomiting in highly emetogenic chemotherapy (ROAD study):
Prospective multicenter, randomized, single blinded, phase III study.
Phase:
Phase 3
Details
Lead Sponsor:
Hallym University Medical Center
Collaborators:
Astellas Pharma Korea, Inc. Korean Cancer Study Group